Value appropriation in hepatitis C
P Lindgren, S Löfvendahl, G Brådvik, O Weiland… - The European Journal of …, 2022 - Springer
Abstract Background In 2015, the Swedish government in an unprecedented move decided
to allocate 150 million€ to provide funding for new drugs for hepatitis C. This was triggered …
to allocate 150 million€ to provide funding for new drugs for hepatitis C. This was triggered …
The value of atorvastatin over the product life cycle in the United States
M Grabner, W Johnson, AM Abdulhalim, A Kuznik… - Clinical …, 2011 - Elsevier
BACKGROUND: US health care reform mandates the reduction of wasteful health care
spending while maintaining quality of care. Introducing new drugs into crowded therapeutic …
spending while maintaining quality of care. Introducing new drugs into crowded therapeutic …
Incentives to innovate
D Lakdawalla, N Sood - The oxford handbook of the economics …, 2012 - books.google.com
There has been perennial concern about high and rapidly rising drug prices in the United
States and in other economies. The pharmaceutical industry and others defend these high …
States and in other economies. The pharmaceutical industry and others defend these high …
Investments in HealthCare, Life Expectancy, and Economic Growth
AA Erakhtina - Problems of Economic Transition, 2022 - Taylor & Francis
Mortality and life expectancy at birth are considered some of the most important aspects of
human economic development. Over the last three centuries, both of these indicators have …
human economic development. Over the last three centuries, both of these indicators have …
[HTML][HTML] Инвестиции в здравоохранение, продолжительность жизни и экономический рост
АД Ерахтина - Всероссийский экономический журнал ЭКО, 2019 - cyberleninka.ru
Ожидаемая продолжительность жизни при рождении и смертность рассматриваются
как важнейшие аспекты экономического развития человечества. За три последних …
как важнейшие аспекты экономического развития человечества. За три последних …
Prescription drug insurance and reimbursement
P Grootendorst - The Elgar Companion to Health Economics …, 2012 - elgaronline.com
The expected utility model predicts that a risk averse consumer, facing the probability p of a
loss of $ L associated with illness, is willing to pay at least the expected loss, $ pL, in …
loss of $ L associated with illness, is willing to pay at least the expected loss, $ pL, in …
Five myths about cancer care in America
DP Goldman, T Philipson - Health Affairs, 2014 - healthaffairs.org
In this commentary we debunk a number of the most common misconceptions about cancer
treatment, such as claims that the war on cancer has been a failure and that treatment costs …
treatment, such as claims that the war on cancer has been a failure and that treatment costs …
Technological adoption in health care–the role of payment systems
PP Barros, X Martinez-Giralt - The BE Journal of Economic Analysis …, 2015 - degruyter.com
This paper examines the incentive to adopt a new technology resulting from common
payment systems, namely mixed cost reimbursement and DRG reimbursement. Adoption is …
payment systems, namely mixed cost reimbursement and DRG reimbursement. Adoption is …
[图书][B] IP & External Consumption Effects: Generalizations from Health Care Markets
TJ Philipson, S Mechoulan, AB Jena - 2006 - Citeseer
A long-standing literature recognizes that an efficient solution in correcting a consumption
externality is applying subsidies or taxes that align private incentives with social ones. An …
externality is applying subsidies or taxes that align private incentives with social ones. An …
[图书][B] Teoria economica e produzione sanitaria
G Clerico - 2009 - books.google.com
Capitolo I-Organizzazione, diritto di scelta e mercati sanitariproblemi e decisioni
dell'acquirente...................................................... 3 2. Capitolo II-Informazione, comunicazione e …
dell'acquirente...................................................... 3 2. Capitolo II-Informazione, comunicazione e …